Abstract: There are different strategies to improve the overall performance of the recursive least-squares (RLS) adaptive filter. In this letter, we focus on the data-reuse approach, aiming to improve ...

Cash Balance: Ended the year with $754 million in cash. Operating Expenses: 35% reduction in pro forma operating expenses year over year. 2026 Cash Operating Expenses: Expected to be under $390 ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2025 Earnings Call Transcript February 25, 2026 Recursion Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.20528, expectations ...

Recursion Pharmaceuticals reported its fourth-quarter 2025 earnings, showcasing a significant beat on both earnings and revenue forecasts. The company reported an EPS of -$0.21, surpassing the ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom ...

Good morning, everyone, and thank you so much for joining us. I want to start by briefly framing where Recursion is today and its journey and evolution. Over the past decade, Recursion has built ...

Earnings call Recursion reported a transformative quarter marked by its initial clinical proof of concept for FAP, a 35% YoY reduction in pro forma operating expenses, and $754 million in year-end ...